Mostrar el registro sencillo del ítem

dc.contributor.authorGil Bernabé, Sara
dc.contributor.authorFeás Rodríguez, Noa
dc.contributor.authorPérez Riesgo, Enrique
dc.contributor.authorCorraliza Gómez, Miriam 
dc.contributor.authorFra Rodríguez, Joaquín
dc.contributor.authorGarcía Rostán, Ginesa
dc.contributor.authorCorraliza Gómez, Miriam 
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.date.accessioned2025-11-21T07:15:13Z
dc.date.available2025-11-21T07:15:13Z
dc.date.issued2025
dc.identifier.issn1559-0097
dc.identifier.issn1046-3976
dc.identifier.urihttp://hdl.handle.net/10498/37983
dc.description.abstractFew studies have analyzed the prevalence of TERT amplification in thyroid cancer, showing discrepancies in various topics. The impact on tumor recurrence and patient survival in papillary thyroid carcinoma (PTC) remains unknown. Thirteen cancer cell lines and 215 tumor samples from 91 patients, who underwent surgery for PTC (41), poorly differentiated thyroid carcinoma (PDC=15), or anaplastic thyroid carcinoma (ATC=35), were analyzed. Clonality, spread with tumor dedifferentiation or metastatic PTC cells, and coexistence with TERTp, BRAF, RAS, and PIK3CA mutations were also investigated. TERT amplification was found in 17%, 20%, and 17% of the PTC, PDC, and ATC, respectively. It was more frequent in follicular variant PTC and PTC with distant metastases (86%, P=0.0448). The cell lines HTh74, SW1736, and T242 had amplification. In PTC, TERT amplification was a subclonal event. The increase in TERT copy number spread in all cases with metastatic PTC cells. In 67% of the PDC and 100% of the ATC, TERT activation segregated with tumor dedifferentiation. TERT amplification correlated with TERTp mutations in PTC (P=0.0313) and PIK3CA mutations in ATC (P=0.0272). TERT amplification significantly correlated with vascular invasion (P=0.03637), distant metastases at diagnosis and/or follow-up (P=0.04482), metachronous distant metastases (P=0.03131), death patient status (P=0.000829), stage at diagnosis (P=0.01995), and stage III/IV at last follow-up (P=0.01552). TERT amplification associated independently with tumor-related recurrence and death. Our study shows that PTC can be stratified into clinically prognostic relevant categories based on the presence or not of TERT amplification in the cells.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.rightsAttribution 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceEndocrine Pathology - 2025, Vol. 36 n. 1 pp. 1-21es_ES
dc.subjectTERT amplificationes_ES
dc.subjectThyroid canceres_ES
dc.subjectMetastaseses_ES
dc.subjectPrognosises_ES
dc.subjectTumor recurrencees_ES
dc.subjectSurvivales_ES
dc.titleTERT Amplification a Risk Stratification Marker in Papillary Thyroid Carcinoma, Significantly Correlated with Tumor Recurrence and Survivales_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1007/S12022-025-09853-4
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Attribution 4.0 Internacional